Liquidia Q2: YUTREPIA Sales Reach $170M, Marking Fourth Straight Profitable Quarter
LQDA has more than doubled off its 52-week low of $19.9.
Summary
Liquidia reported Q2 2026 net product sales of $170.4 million for YUTREPIA, its fourth consecutive profitable quarter, with net income of $74.7 million and a cash balance of $284.2 million. The company is advancing 10 clinical studies and updated its corporate presentation.
Key Events · Earnings and Guidance · LQDA
-
YUTREPIA Sales Surge 31% Q/Q
Driven by strong prescription growth and high conversion rates, net product sales climbed to $170.4 million in Q2 2026, up from $129.9 million in Q1 2026.
-
Fourth Consecutive Profitable Quarter
Net income reached $74.7 million, or $0.74 per diluted share, with adjusted EBITDA of $96.3 million, underscoring operating leverage as sales scale.
-
Cash Balance Strengthens to $284.2M
Cash and cash equivalents rose by $61.4 million from Q1 2026, providing ample runway to fund 10 ongoing or planned clinical studies.
-
Broad Clinical Pipeline Advancing
Ten studies are ongoing or initiating within the next year, including the pivotal Re-Spire trial for L606 in PH-ILD and new indications like PH-COPD and SSc-Raynaud's.
Analysis · LQDA · Life Sciences
A standout quarter for Liquidia saw YUTREPIA net product sales jump 31% sequentially to $170.4 million, fueling net income of $74.7 million and adjusted EBITDA of $96.3 million. The company is now self-funding an ambitious pipeline of 10 clinical studies, including the pivotal Re-Spire trial for L606, while building a cash war chest of $284.2 million. These results cement the commercial launch trajectory and validate the inhaled treprostinil franchise, though ongoing patent litigation with United Therapeutics remains a material overhang.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $87.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $19.90 to $93.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.